Galmed Pharmaceuticals Logo
IL0011313900
A1XFUX
GLMD

Galmed Pharmaceuticals

Loading quotes...

Forecast

Buy
  10
Hold
  6
Sell
  0

Discussions in the community

There is no discussion about this asset yet.

Start discussion

  • Galmed: Aramchol combined with enzalutamide leads to 3–4‑fold increased cell death in preclinical prostate cancer study

    Galmed published preclinical data showing that the combination of Aramchol with enzalutamide increased cell death by 3–4‑fold versus enzalutamide alone in a VCaP prostate cancer cell line. The interaction strengthened over time; earlier data had already shown interactions of Aramchol with docetaxel. Galmed plans to engage in talks with potential partners based on a filed patent application and to further evaluate the combination. » More on de.investing.com


  • Galmed: new oral film formulation of Aramchol achieves significantly higher CNS exposure

    Galmed reports that a new oral film formulation of the active substance Aramchol achieves about 150% higher systemic bioavailability and roughly 300% higher central nervous system (CNS) exposure compared with conventional oral administration. The fast‑dissolving film enables buccal/sublingual uptake, reduces first‑pass metabolism and was developed to treat dysphagia in Parkinson’s patients. Aramchol acts as an inhibitor of stearoyl‑CoA desaturase 1 and showed a dose‑dependent reduction of alpha‑synuclein aggregation in earlier in vitro data with a confirmed safety profile. Galmed views the program as partner‑ready and highlights a global Parkinson’s market of more than USD 6 billion. » More on de.investing.com


  • Galmed: new Aramchol‑Meglumin formulation achieves significantly higher bioavailability

    Galmed reports from a pharmacokinetic phase‑1 study that Aramchol‑Meglumin granulate in single doses shows roughly five‑fold and three‑fold higher bioavailability compared with 300 mg tablets of the free Aramchol acid. The goal is a once‑daily 400 mg dose that could replace ongoing studies using 300 mg twice daily and reduce manufacturing costs by around 50%. The company highlights improved adherence prospects and is also exploring oncological indications; according to InvestingPro the stock appears undervalued at its current valuation and has high short‑term liquidity. » More on de.investing.com


  • Galmed teams with Tissue Dynamics to develop human models for cardiac fibrosis

    Galmed and Tissue Dynamics have launched a collaboration to develop a human model for chronic cardiac fibrosis that combines vascularized heart organoids with embedded metabolic sensors and real‑time monitoring. The aim is to investigate Aramchol‑based therapeutic approaches and to apply Galmed’s expertise in SCD1 biology to modulate fibrotic signaling pathways. The model is intended to reproduce chronic remodeling after myocardial infarction and heart failure with preserved ejection fraction, shortcomings of existing animal models and short‑term assays. Galmed’s stock is currently trading low with a small market capitalization; investors are expecting the quarterly report on May 20. » More on de.investing.com


  • Galmed partners with Tel Aviv University to test Aramchol against brain metastases

    Galmed announced a research collaboration with Ramot at Tel Aviv University to evaluate Aramchol, a brain‑penetrant SCD1 inhibitor, as a targeted therapy for metastatic brain cancer. The collaboration combines genomic analyses and modeling to assess efficacy in p53‑deficient brain metastases. The announcement recently lifted the stock by 33%, but the share remains significantly down on a six‑month view. Galmed aims to advance Aramchol beyond its prior liver disease indications into oncological applications. » More on de.investing.com

Financials

In the last quarter, Galmed Pharmaceuticals had revenue of €0 and net profit of -€2.39m
(EUR) June 2026
YoY
Revenue 0 -
Gross profit 0 -
Net profit -2.39m 12.71%
EBITDA -2.43m 14.87%

Fundamentals

Metric Value
Market capitalization
€4.34m
Number of shares
1.03m
52-week high/low
€11.98 - €2.98
Dividends No
Beta
0.67
P/E ratio
-
PEG ratio
-
P/B ratio
-
P/S ratio
-

Company profile

Galmed Pharmaceuticals Ltd., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment of liver diseases. It develops Aramchol, an oral therapy, which is in Phase III study for the treatment of non-alcoholic steato-hepatitis (NASH) in patients with overweight or obesity and who are pre-diabetic or type-II-diabetes mellitus. The company also evaluates Aramchol through ARRIVE Study, a Phase IIa clinical trial with HIV-associated non-alcoholic fatty liver disease and lipodystrophy. In addition, it engages in the development of Amilo-5MER, a 5 amino acid synthetic peptide methionine, threonine, alanine, aspartic acid, and valine. It has a research agreement with Gannex Pharma Co., Ltd. to develop a combination therapy of ASC41 (THR-beta agonist) and Aramchol (SCD 1 inhibitor) for the treatment of NASH; a research and development collaboration agreement with MyBiotics Pharma Ltd. to identify the selected microbiome repertoire associated with the response to Aramchol; and a license agreement with Samil Pharma. Co., Ltd. for the commercialization of Aramchol in the Republic of Korea. Galmed Pharmaceuticals Ltd. was founded in 2000 and is headquartered in Tel Aviv, Israel.

Name
Galmed Pharmaceuticals
CEO
Allen Baharaff
Headquarters Ramat Gan, ta
Israel
Website
Sector
Materials
Industry
Chemicals
IPO
13/03/2014
Employees 6

Ticker symbols

Exchange Symbol
NASDAQ
GLMD
Frankfurt
GPH.F
🍪

Parqet  uses cookies. Learn more